New CAR-T therapy shows promise in tough leukemia cases
NCT ID NCT05350787
First seen Feb 19, 2026 · Last updated Jun 18, 2026 · Updated 18 times
Summary
This early-phase study tested a new immune cell therapy called ThisCART19A in 10 adults with a hard-to-treat type of leukemia (B-ALL) that had come back or stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see how well the therapy works. Researchers tracked side effects and measured how many patients achieved remission within three months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-ALL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The First Hospital of Zhejiang Medical Colleage Zhejiang University
Hangzhou, Zhejiang, 310003, China
-
The first affiliated hospital of medical college of zhejiang university
Hangzhou, Zhejiang, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.